QR код

Nirmatrelvir/ritonavir reduced mortality in severe or critical COVID-19 patients: a multicenter retrospective cohort study

BackgroundPatients with severe or critical coronavirus disease 2019 (COVID-19) remain at a high risk of mortality. Although nirmatrelvir/ritonavir has demonstrated efficacy in non-severe COVID-19 patients with high-risk factors, its effectiveness in hospitalized patients with severe or critical COVI...

Повний опис

Збережено в:
Автори: Heng Zhao, Wanting Meng, Xing Lv, Shaokui Si, Shunjun Wu, Jing Li, Zhigui Cai, Ruoqi Jin, Ling Yang, Chenyao Li, Liqiang Song
Формат: Artigo
Мова:Inglês
Опубліковано: Frontiers Media S.A. 2026-02-01
Серія:Frontiers in Medicine
Предмети:
COVID-19
critical illness
mortality
nirmatrelvir/ritonavir
severe disease
Онлайн доступ:https://www.frontiersin.org/articles/10.3389/fmed.2026.1747565/full
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси